ANI Pharma Proxy: Exec Comp Details for FY24
Ticker: ANIP · Form: DEF 14A · Filed: Apr 10, 2025 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | DEF 14A |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
ANI Pharma proxy out - exec comp for 2024 is in. Check Nikhil Lalwani's equity awards.
AI Summary
ANI Pharmaceuticals Inc. filed its DEF 14A on April 10, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on compensation for board members and key executives, such as Nikhil Lalwani, who is listed as a member of the board and received compensation related to equity awards. The company's principal executive offices are located at 210 Main Street West, Baudette, MN.
Why It Matters
This filing provides transparency into how ANI Pharmaceuticals compensates its top executives and board members, which can influence investor decisions and perceptions of corporate governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing detailing executive compensation and corporate governance, with no immediate negative financial or operational news.
Key Players & Entities
- ANI Pharmaceuticals Inc. (company) — Filer of the DEF 14A
- Nikhil Lalwani (person) — Board member and recipient of equity awards
- 210 Main Street West, Baudette, MN (location) — Company's principal executive offices
- 2024-12-31 (date) — Fiscal year end for compensation details
- 20250410 (date) — Filing date of the DEF 14A
FAQ
What was the total compensation for key executives in fiscal year 2024?
The filing provides details on equity awards and other compensation components for individuals like Nikhil Lalwani, but specific total dollar amounts for all executives are not immediately summarized in the provided text.
Who are the named executive officers and directors for the fiscal year 2024?
The filing mentions Nikhil Lalwani as a member, and other members such as Arthur Przybyl and Patrick Walsh are listed in relation to prior years' compensation, indicating they are likely directors or officers.
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding the company's annual meeting, including the election of directors and executive compensation details, as required by SEC regulations.
When was ANI Pharmaceuticals Inc. previously known by another name?
ANI Pharmaceuticals Inc. was formerly known as BIOSANTE PHARMACEUTICALS INC. until December 28, 1999, and before that as BEN ABRAHAM TECHNOLOGIES INC.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 10, 2025 by Nikhil Lalwani regarding ANI PHARMACEUTICALS INC (ANIP).